BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™), today announced that it has filed for patent protection for certain in vivo recombinant production techniques of its DXL™ antibodies. The techniques and patents provide significant protection for InNexus’ latest scientific achievement and growing product pipeline.
